InvestmentJul 7, 2026, 07:32 AM
MeiraGTx Secures Up to $400M Funding from Oberland Capital
AI Summary
MeiraGTx Holdings plc announced an agreement with Oberland Capital Management LLC for an investment of up to $400 million. This funding package includes up to $375 million in non-dilutive capital through capped royalty payments on certain products and up to $25 million in equity. The capital will support the potential commercialization of the company's late-stage programs for X-linked retinitis pigmentosa (XLRP) and radiation-induced xerostomia.
Key Highlights
- Secured up to $400M investment from Oberland Capital.
- Includes up to $375M in non-dilutive royalty funding.
- Includes up to $25M in equity investment.
- Initial funding of $135M ($125M royalty, $10M equity).
- Additional $50M tied to AAV2-hAQP1 Phase 2 data in 2027.
- Additional $50M tied to bota-vec regulatory approval in 2027.
- Additional $50M tied to AAV2-hAQP1 regulatory approval in 2028.
- Further $100M available for new products/business development.
Price Impact
More from MGTX